Therapy Type: Small Molecule (timeline)
Target Type: Cholinergic System (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
PF-06852231 is a small-molecule cholinergic modulator. No preclinical information about this compound is published.
In July 2017, Pfizer began enrolling healthy volunteers for a safety, tolerability, and pharmacokinetics study of this compound at the company's clinical research unit in Brussels. In January 2018, Pfizer announced it was discontinuing its research and development work across neuroscience indications, and this compound was discontinued.
Last Updated: 02 Feb 2018
No Available Further Reading